Presentations & Publications

We are proud of our scientific progress, much of which has been documented via various presentations and publications.

Since 2011, our proprietary platform has enabled the design of three new clinical drug candidates, resulting in four clinical programs. Our scientific progress has been documented in various national and international presentations and publications.

March 2021	Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease Dr. Claire Langrish et al. Journal of Immunology, March 5, 2021
December 2020	Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients With Heavily Pretreated Immune Thrombocytopenia Dr. David Kuter et al. ASH Oral Presentation, December 5, 2020
October 2020	Mechanisms of Topical Bruton Tyrosine Kinase Inhibitor PRN473 in Immune‑Mediated Models of Skin Disease Dr. Yan Xing et al. EADV Poster Presentation, October 29, 2020
October 2020	Metabolism-Mediated Drug Interactions Between Ritonavir and Oral BTK Inhibitor Rilzabrutinib in Rats Dr. Sibel Ucpinar et al. ACCP Poster Presentation, October 27, 2020
October 2020	A Thorough QT Study to Evaluate the Effects of Oral Rilzabrutinib Administered Alone and With Ritonavir to Achieve Supratherapeutic Concentrations in Healthy Subjects Dr. Sibel Ucpinar et al. ACCP Poster Presentation, October 27, 2020
July 2020	Phase I/II, Open-Label, Ongoing Study of Rilzabrutinib (PRN1008), an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Heavily Pretreated Immune Thrombocytopenia Dr. David Kuter et al. ISTH, July 12, 2020
June 2020	BELIEVE-PV Phase II Part B Study: Extended Treatment With PRN1008 (Rilzabrutinib) For Patients With Pemphigus Dr. Dedee Murrell et al. AAD June 12th, 2020
June 2020	Safety and Efficacy of Rilzabrutinib (PRN1008), an Oral Bruton Tyrosine Kinase Inhibitor, in Relapsed/Refractory Patients With Primary or Secondary Immune Thrombocytopenia: Phase I/II Adaptive Study Dr. David Kuter et al. EHA June 12th, 2020

Advancing Promising Therapies

See Our Pipeline